ARTICLE | Clinical News
Avax starts Phase II cancer trial
March 28, 2000 8:00 AM UTC
AVXT started a U.S. Phase II study of M-Vax, its autologous therapeutic cancer vaccine, to treat patients with stage IV melanoma who have measurable disease limited primarily to lung metastases. ...